Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152125 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP3A4MAPTTP53LMNA | |
| SCHEMBL3845560 | 0.92 | PTPN2 (0.36) | SMN1; SMN2CYP3A4MAPTTP53LMNA | |
| SCHEMBL5172821 | 0.91 | CA2 (0.41) | LMNAESR1RORCCA2TDP1 | |
| SCHEMBL2214509 | 0.91 | CA2 (0.41) | LMNAESR1RORCCA2TDP1 | |
| SCHEMBL3845724 | 0.91 | CA2 (0.41) | LMNAESR1RORCCA2TDP1 | |
| SCHEMBL5149829 | 0.91 | CA2 (0.41) | LMNAESR1RORCCA2TDP1 | |
| SCHEMBL3844952 | 0.88 | RORC (0.33) | LMNARORCCA2TDP1STS | |
| SCHEMBL3845720 | 0.87 | NR1H2 (0.33) | SMN1; SMN2CYP3A4MAPTTP53LMNA | |
| SCHEMBL3845258 | 0.87 | TP53 (0.30) | SMN1; SMN2CYP3A4MAPTTP53 | |
| SCHEMBL3846780 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | claimed |
| EP-1957515-A2 | PRODRUG ERbeta-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | claimed |
| WO-2007062877-A2 | PRODRUG ERβ-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | claimed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | claimed |
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1957515-A2 | PRODRUG ERbeta-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062877-A2 | PRODRUG ERβ-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | SMN1; SMN2 4858/4885CYP3A4 54/4885MAPT 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.